Subtype-Specific Counseling for Thyroid Cancer Patients Patients with papillary, follicular, or Oncocytic (Hrthle cell) thyroid cancer should not be told or assume that GLP-1 therapy caused their disease in the absence of supporting evidence
These drugs are already breaking weight-loss records: in trials involving people with knee osteoarthritis, retatrutide led to an average weight loss of up to 29% after 68 weeks, about 71 pounds, and a reduction in knee pain
Eating smaller, more frequent meals rather than large portions reduces gastric distress
GLP-1s include Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes counterpart Ozempic, along with Eli Lilly's popular weight loss treatment Zepbound and diabetes injection Mounjaro
While compounded formulations are not FDA-approved as finished products, they use FDA-approved active pharmaceutical ingredients and follow established pharmaceutical compounding practices
Compounded tirzepatide was the second